Per Artikel

Riset dan Pengabdian Masyarakat Do Research Sosial Service and Innovation

Id	Authors	Full Names	Author S Id	Title	Year	Source Title	Volume	Issue	Art No	Page Start	Page End	Page Count	Cited By	Link	Affiliations	Authors With Affiliations	Abstract	Author Keywords	Index Keywords	Funding Details	Funding Text	Publisher	Issn	Isbn	Pubmed Id	Document Type	Sjr Best Quartile	Sjr	Sjr Rank
Display # Page 1 of 50 Start Prev 1 2 3 4 5 6 7 8 9 10 Next End
(1)
No records
205	Ambarsari C.G.; Tandri C.C.; Situmorang G.R.	Ambarsari, Cahyani Gita (57211850895); Tandri, Chika Carnation (58612308600); Situmorang, Gerhard Reinaldi (57190001213)	57211850895; 58612308600; 57190001213	Urinary extracellular vesicles: Potential biomarkers for vesicoureteral reflux	2024	Vesicoureteral Reflux: From Diagnosis to Treatment				1	31	30	0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85188558589&partnerID=40&md5=8a9d50d7da10ee591511aac119604866	Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Department of Child Health, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; University of Nottingham, Nottingham, United Kingdom; Medical Technology Cluster, Indonesian Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Urology, Cipto Mangunkusumo Hospital, Jakarta, Indonesia	Ambarsari C.G., Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Department of Child Health, Cipto Mangunkusumo Hospital, Jakarta, Indonesia, University of Nottingham, Nottingham, United Kingdom, Medical Technology Cluster, Indonesian Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Tandri C.C., Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Situmorang G.R., Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Department of Urology, Cipto Mangunkusumo Hospital, Jakarta, Indonesia	Vesicoureteral reflux (VUR) is characterized by the backward flow of urine from the bladder to the upper urinary tract, causing kidney damage if left untreated. However, the current diagnostic method, voiding cystourethrography (VCUG), is invasive, potentially risky, and may cause anxiety, especially for young patients and their caregivers. Urinary extracellular vesicles (uEVs) are small vesicles originating from the renal tubular system that carry lipids, proteins, and RNAs for intercellular communication and regulation. uEVs have emerged as promising human biofluid-derived biomarkers in various kidney diseases. This chapter explores the potential of uEVs as noninvasive biomarkers for diagnosing VUR, monitoring its progression, and determining the extent of kidney damage. Previously, serum inflammatory markers have been identified as factors associated with kidney fibrosis in reflux nephropathy, but these may simply be a reflection of systemic inflammation rather than of a specific condition. Meanwhile, current research on uEVs in VUR remains limited. One study has identified vitronectin, a uEV-derived protein, as a predictor of VUR induced by spinal cord injury (sensitivity = 80%, specificity = 82.9%, area under the curve (AUC) = 0.795). Another study, focusing on pediatric VUR, showed that patients with kidney fibrosis had significantly higher urinary neutrophil gelatinaseassociated lipocalin (uNGAL) values than those without kidney fibrosis (1.49 ng/mL vs. 0.58 ng/mL, p < 0.001). However, apart from kidney fibrosis, uNGAL also increases in the contexts of AKI and pediatric urinary tract infections, indicating that uNGAL is not specific as a single marker for VUR. These findings highlight the importance of identifying biomarkers derived from entities, such as uEVs, that are specific to the urinary system and are not affected by systemic factors In summary, uEVs offer crucial insights into urinary tract processes and have broad potential for diagnosing, treating, and forecasting kidney and urinary tract diseases, including VUR. Future studies to test their role should encompass larger sample sizes, standardized protocols, and rigorous validation. © 2024 Nova Science Publishers, Inc. All rights reserved.	Diagnostic; Fibrosis; Invasive; Kidney damage; Urinary tract				Nova Science Publishers, Inc.		979-889113505-5; 979-889113444-7		Book chapter	#N/A	#N/A	#N/A	View
00015385(1)
No records
365	Kohar K.; Sanjaya I.S.; Amirah S.; Yumnanisha D.A.; Ambari A.M.	Kohar, Kelvin (57536819200); Sanjaya, Indira Saraswati (59092605900); Amirah, Shakira (57782995800); Yumnanisha, Defin Allevia (59092606000); Ambari, Ade Meidian (57189576921)	57536819200; 59092605900; 57782995800; 59092606000; 57189576921	The potential of triglyceride-glucose index in improving the prediction of post-percutaneous coronary intervention clinical outcomes: a systematic review and meta-analysis	2024	Acta Cardiologica							0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85192539078&doi=10.1080%2f00015385.2024.2349829&partnerID=40&md5=0d3b8aa6dffa89ee2f5e3f8bde27378c	Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Cardiology and Vascular Medicine, National Cardiovascular Center Harapan Kita, Universitas Indonesia, Jakarta, Indonesia	Kohar K., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Sanjaya I.S., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Amirah S., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Yumnanisha D.A., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Ambari A.M., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, National Cardiovascular Center Harapan Kita, Universitas Indonesia, Jakarta, Indonesia	Introduction: Despite percutaneous coronary intervention is the current preferred reperfusion modality, the incidence of major adverse cardiovascular events (MACE) is still high. Currently, GRACE score is used for predicting PCI outcomes. The TyG (triglyceride-glucose) index, a potential predictor based on insulin resistance of cardiovascular disease, has not been considered in the GRACE score. Objective: To assess the potential of the TyG index in predicting cardiovascular adverse clinical outcomes in patients undergoing PCI. Method: Following PRISMA guidelines, the authors reviewed literature from five databases. We included studies investigating post-PCI outcomes based on the TyG index level. Effect size was estimated using RevMan to calculate pooled odds ratio and mean difference, and R software to perform diagnostic test accuracy. Results: Overall, 31,671 post-PCI patients with acute coronary syndrome were included in this study. A significant difference in TyG index was found between patients who experienced MACE and those who did not [MD: 0.3 (0.2–0.4), p <.05]. Higher TyG index was strongly correlated with higher MACE [OR: 2.01 (1.45–2.77), p <.05], especially revascularization [OR: 2.40 (1.72–3.36), p <.05], followed by myocardial infarction [OR: 1.80 (2.41–2.86), p <.05], death [OR: 1.36 (0.86–2.15), p =.19], and stroke [OR: 1.09 (0.79–1.50), p =.59]. Tyg Index showed 55% sensitivity, 60% specificity, and 0.612 accuracy. The addition of the TyG index to the GRACE scoring improved the predictive model’s AUC (0.746 vs. 0.809). Conclusion: This systematic review and meta-analysis comprises evidence-based results for the correlation of TyG index and post-PCI outcomes, demonstrating modest sensitivity, specificity, accuracy, and enhanced predictive value of GRACE score. © 2024 Belgian Society of Cardiology.	major adverse cardiovascular effect; percutaneous coronary intervention; prediction model; Triglyceride-glucose index				Taylor and Francis Ltd.	00015385			Article	Q3	355	13556	View
00016071(1)
No records
181	Soemarko D.S.; Jahja F.E.; Adi N.P.; Anestherita F.; Fitriani D.Y.	Soemarko, Dewi Sumaryani (57192889490); Jahja, Felicia Erika (57224583934); Adi, Nuri Purwito (57023786200); Anestherita, Fitri (57193003531); Fitriani, Dewi Yunia (57224589606)	57192889490; 57224583934; 57023786200; 57193003531; 57224589606	Association between COVID-19 Post-infection and Work Capacity among Healthcare Workers in the National Referral Hospital in Indonesia	2024	Acta Medica Philippina	58	5		57	61	4	0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85189467247&doi=10.47895%2famp.vi0.6739&partnerID=40&md5=37ef9cfa417b725b2dfe1cfb9f088827	Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia; Occupational and Environmental Health Research Centre IMERI, Faculty of Medicine, Universitas Indonesia, Indonesia; Occupational Medicine Specialist Programme, Faculty of Medicine, Universitas Indonesia, Indonesia; Physical Medicine and Rehabilitation Department, Faculty of Medicine, Universitas Indonesia, Indonesia	Soemarko D.S., Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia, Occupational and Environmental Health Research Centre IMERI, Faculty of Medicine, Universitas Indonesia, Indonesia; Jahja F.E., Occupational Medicine Specialist Programme, Faculty of Medicine, Universitas Indonesia, Indonesia; Adi N.P., Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia, Occupational and Environmental Health Research Centre IMERI, Faculty of Medicine, Universitas Indonesia, Indonesia; Anestherita F., Physical Medicine and Rehabilitation Department, Faculty of Medicine, Universitas Indonesia, Indonesia; Fitriani D.Y., Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia, Occupational and Environmental Health Research Centre IMERI, Faculty of Medicine, Universitas Indonesia, Indonesia	Background. Patients who had severe COVID-19 infection were thought to be one of the factors affecting the suitability of work capacity. Functional capacity can be measured by 6-minute walking test (6MWT). Some particular jobs have a minimum functional capacity to be met. Objectives. The aim of this research is to determine the relationship between severity of COVID-19 infection and work capacity among post-infected healthcare workers in the National Referral Hospital. Methods. A cross-sectional study among healthcare workers who had COVID-19 infection from June to July 2021, and had undergone functional capacity examination from September to November 2021 was conducted. Data processing was carried out by collecting data from medical records of infected healthcare workers. Bivariate analysis statistic test was done to determine the association between degree of severity and work capacity. Determination of the suitability of work capacity was done by comparing the results of the functional capacity examination with the minimum estimated matabolic equivalents (METs) needs of workers. Results. A total of 102 employees data from ages 25 to 58 years were collected. The result showed that 81 employees had unsuitable work capacity with most of them coming from the mild infected group (83.3%). Conclusion. There is no significant relationship (p>0.05) between age, gender, BMI, sequelae, comorbidities, and degree of severity of COVID-19 infection and work capacity among healthcare workers. Even though there is no signficant relationship between severity of COVID-19 and work capacity, this research shows there are more than 50% post-infected healthcare workers who have unsuitable work capacity. © 2024 University of the Philippines Manila. All rights reserved.	COVID-19; healthcare workers; work capacity				University of the Philippines Manila	00016071			Article	Q4	118	24373	View
00029637(4)
No records
136	Marsh K.; Akl E.; Achan J.; Alzahrani M.; Kevin Baird J.; Bousema T.; Gamboa D.; Lacerda M.; Mendis K.; Penny M.; Schapira A.; Sovannaroth S.; Wongsrichanalai C.; Tiffany A.; Li X.; Shutes E.; Schellenberg D.; Alonso P.; Lindblade K.A.	Marsh, Kevin (7201684011); Akl, Elie (6603011139); Achan, Jane (23471656200); Alzahrani, Mohammed (57794260900); Kevin Baird, J. (58995916200); Bousema, Teun (6506709831); Gamboa, Dionicia (20734091100); Lacerda, Marcus (57259514700); Mendis, Kamini (7004958149); Penny, Melissa (24740980300); Schapira, Allan (7102634396); Sovannaroth, Siv (55874133800); Wongsrichanalai, Chansuda (7005248613); Tiffany, Amanda (55828478800); Li, Xiaohong (59075150900); Shutes, Erin (8373997700); Schellenberg, Davi	7201684011; 6603011139; 23471656200; 57794260900; 58995916200; 6506709831; 20734091100; 57259514700; 7004958149; 24740980300; 7102634396; 55874133800; 7005248613; 55828478800; 59075150900; 8373997700; 7003483370; 57912441200; 6603327957	Development of WHO Recommendations for the Final Phase of Elimination and Prevention of Re-Establishment of Malaria	2024	American Journal of Tropical Medicine and Hygiene	110	4		3	10	7	6	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186567748&doi=10.4269%2fajtmh.22-0768&partnerID=40&md5=a5def92f93d14ad8a305231c197b81a3	Centre for Tropical Medicine and Global Health, University of Oxford, United Kingdom; Department of Internal Medicine, American University of Beirut, Lebanon, Lebanon; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada; Malaria Consortium, London, United Kingdom; Public Health Agency, Ministry of Health, Makkah, Saudi Arabia; Oxford University Clinical Research Unit, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Department of Medical Microbiology, Radboud University Medical Center, Radboud, Netherlands; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru; Tropical Medicine Foundation Dr Heitor Vieira Dourado, Manaus, Brazil; Department of Parasitology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka; Swiss Tropical and Public Health Institute, Allschwil, Switzerland; University of Basel, Basel, Switzerland; Bicol University College of Medicine, Legazpi City, Philippines; National Malaria Program, Ministry of Health, Phnom Penh, Cambodia; Independent Consultant, Bangkok, Thailand; Global Malaria Programme, WHO, Geneva, Switzerland	Marsh K., Centre for Tropical Medicine and Global Health, University of Oxford, United Kingdom; Akl E., Department of Internal Medicine, American University of Beirut, Lebanon, Lebanon, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada; Achan J., Malaria Consortium, London, United Kingdom; Alzahrani M., Public Health Agency, Ministry of Health, Makkah, Saudi Arabia; Kevin Baird J., Centre for Tropical Medicine and Global Health, University of Oxford, United Kingdom, Oxford University Clinical Research Unit, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Bousema T., Department of Medical Microbiology, Radboud University Medical Center, Radboud, Netherlands; Gamboa D., Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru; Lacerda M., Tropical Medicine Foundation Dr Heitor Vieira Dourado, Manaus, Brazil; Mendis K., Department of Parasitology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka; Penny M., Swiss Tropical and Public Health Institute, Allschwil, Switzerland, University of Basel, Basel, Switzerland; Schapira A., Bicol University College of Medicine, Legazpi City, Philippines; Sovannaroth S., National Malaria Program, Ministry of Health, Phnom Penh, Cambodia; Wongsrichanalai C., Independent Consultant, Bangkok, Thailand; Tiffany A., Global Malaria Programme, WHO, Geneva, Switzerland; Li X., Global Malaria Programme, WHO, Geneva, Switzerland; Shutes E., Global Malaria Programme, WHO, Geneva, Switzerland; Schellenberg D., Global Malaria Programme, WHO, Geneva, Switzerland; Alonso P., Global Malaria Programme, WHO, Geneva, Switzerland; Lindblade K.A., Global Malaria Programme, WHO, Geneva, Switzerland	The WHO recommends that all affected countries work toward the elimination of malaria, even those still experiencing a high burden of disease. However, malaria programs in the final phase of elimination or those working to prevent re-establishment of transmission after elimination could benefit from specific evidence-based recommendations for these settings as part of comprehensive and quality-controlled malaria guidelines. The WHO convened an external guideline development group to formulate recommendations for interventions to reduce or prevent malaria transmission in areas with very low– to low-transmission levels and those that have eliminated malaria. In addition, several interventions that could be deployed in higher burden areas to accelerate elimination, such as mass drug administration, were reviewed. Systematic reviews were conducted that synthesized and evaluated evidence for the benefits and harms of public health interventions and summarized critical contextual factors from a health systems perspective. A total of 12 recommendations were developed, with five related to mass interventions that could be deployed at higher transmission levels and seven that would be most appropriate for programs in areas close to elimination or those working to prevent re-establishment of transmission. Four chemoprevention, two active case detection, and one vector control interventions were positively recommended, whereas two chemoprevention and three active case detection interventions were not recommended by the WHO. None of the recommendations were classified as strong given the limited and low-quality evidence base. Approaches to conducting higher quality research in very low– to low-transmission settings to improve the strength of WHO recommendations are discussed. © 2024 American Society of Tropical Medicine and Hygiene. All rights reserved.		Antimalarials; Chemoprevention; Humans; Malaria; Mass Drug Administration; World Health Organization; antimalarial agent; Article; attitude to health; chemoprophylaxis; consensus development; disease burden; epidemiological surveillance; evidence based medicine; health care; health care planning; health care policy; malaria; malaria control; mass drug administration; practice guideline; public health service; vector control; human; malaria; World Health Organization	Bill and Melinda Gates Foundation, BMGF, (OPP 1209843); Bill and Melinda Gates Foundation, BMGF	Financial support: The WHO received financial support from the Bill & Melinda Gates Foundation (OPP 1209843) for this work.	American Society of Tropical Medicine and Hygiene	00029637		38118172	Article	Q1	1042	3942	View
398	Indrihutami K.; Chand K.; Fahmia R.; Rahardjani M.; Wulandari F.; Subekti D.; Noviyanti R.; Soebandrio A.; Mallisa N.T.; Mardika I.M.; Budiman W.; Suriswan I.; Ertanto Y.; Chen M.-C.; Murshedkar T.; Abebe Y.; Sim B.K.L.; Hoffman S.L.; Richie T.L.; Chen S.; Elyazar I.R.F.; Ekawati L.L.; Baird J.K.; Nelwan E.J.	Indrihutami, Khoriah (59019138700); Chand, Krisin (15077006400); Fahmia, Rizka (59019138800); Rahardjani, Mutia (57397771600); Wulandari, Fitria (57397960200); Subekti, Decy (6603632507); Noviyanti, Rintis (6508241752); Soebandrio, Amin (8602893200); Mallisa, Noch T. (59015864400); Mardika, I. Made (59018327200); Budiman, Waras (57219944920); Suriswan, Irwan (59019961900); Ertanto, Yogi (57211856711); Chen, Mei-Chun (57679115300); Murshedkar, Tooba (57189236512); Abebe, Yonas (56472623000); Sim,	59019138700; 15077006400; 59019138800; 57397771600; 57397960200; 6603632507; 6508241752; 8602893200; 59015864400; 59018327200; 57219944920; 59019961900; 57211856711; 57679115300; 57189236512; 56472623000; 7006646214; 7202543944; 57203053630; 59016699500; 6506894785; 55600338600; 15921267800; 14527452900	Implementation of a Randomized, Placebo-Controlled Trial of Live Attenuated Malaria Sporozoite Vaccines in an Indonesian Military Study Population	2024	American Journal of Tropical Medicine and Hygiene	110	5		892	901	9	0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85192113869&doi=10.4269%2fajtmh.23-0597&partnerID=40&md5=b584381f8da125e76cef7c164bcbc56b	Oxford University Clinical Research Unit Indonesia, Jakarta, Indonesia; Eijkman Research Center for Molecular Biology, National Research & Innovation Agency, West Java, Cibinong, Indonesia; EXEINS Health Initiative, Jakarta, Indonesia; Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Presidential Staff Office, Republic of Indonesia, Jakarta, Indonesia; Gatot Soebroto Army Hospital, Jakarta, Indonesia; Muhammadiyah University, East Java, Surabaya, Indonesia; Army Medical Center, Army of the Republic of Indonesia, Jakarta, Indonesia; Sanaria Inc., Rockville, MD, United States; StatPlus, Inc, Taipei, Taiwan; Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Division of Tropical Medicine and Infectious Disease, Department of Internal Medicine, Cipto Mangunkusumo Hospital, Jakarta, Indonesia	Indrihutami K., Oxford University Clinical Research Unit Indonesia, Jakarta, Indonesia; Chand K., Oxford University Clinical Research Unit Indonesia, Jakarta, Indonesia; Fahmia R., Oxford University Clinical Research Unit Indonesia, Jakarta, Indonesia; Rahardjani M., Oxford University Clinical Research Unit Indonesia, Jakarta, Indonesia; Wulandari F., Oxford University Clinical Research Unit Indonesia, Jakarta, Indonesia; Subekti D., Oxford University Clinical Research Unit Indonesia, Jakarta, Indonesia; Noviyanti R., Eijkman Research Center for Molecular Biology, National Research & Innovation Agency, West Java, Cibinong, Indonesia, EXEINS Health Initiative, Jakarta, Indonesia; Soebandrio A., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Mallisa N.T., Presidential Staff Office, Republic of Indonesia, Jakarta, Indonesia; Mardika I.M., Gatot Soebroto Army Hospital, Jakarta, Indonesia; Budiman W., Muhammadiyah University, East Java, Surabaya, Indonesia; Suriswan I., Gatot Soebroto Army Hospital, Jakarta, Indonesia; Ertanto Y., Army Medical Center, Army of the Republic of Indonesia, Jakarta, Indonesia; Chen M.-C., Sanaria Inc., Rockville, MD, United States; Murshedkar T., Sanaria Inc., Rockville, MD, United States; Abebe Y., Sanaria Inc., Rockville, MD, United States; Sim B.K.L., Sanaria Inc., Rockville, MD, United States; Hoffman S.L., Sanaria Inc., Rockville, MD, United States; Richie T.L., Sanaria Inc., Rockville, MD, United States; Chen S., StatPlus, Inc, Taipei, Taiwan; Elyazar I.R.F., Oxford University Clinical Research Unit Indonesia, Jakarta, Indonesia; Ekawati L.L., Oxford University Clinical Research Unit Indonesia, Jakarta, Indonesia, Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Baird J.K., Oxford University Clinical Research Unit Indonesia, Jakarta, Indonesia, Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Nelwan E.J., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Division of Tropical Medicine and Infectious Disease, Department of Internal Medicine, Cipto Mangunkusumo Hospital, Jakarta, Indonesia	Malaria eradication efforts prioritize safe and efficient vaccination strategies, although none with high-level efficacy against malaria infection are yet available. Among several vaccine candidates, SanariaVR PfSPZ Vaccine and Sanaria PfSPZ-CVac are, respectively, live radiation- and chemo-attenuated sporozoite vaccines designed to prevent infection with Plasmodium falciparum, the leading cause of malaria-related morbidity and mortality. We are conducting a randomized normal saline placebo-controlled trial called IDSPZV1 that will analyze the safety, tolerability, immunogenicity, and efficacy of PfSPZ Vaccine and PfSPZ-CVac administered pre-deployment to malaria-naive Indonesian soldiers assigned to temporary duties in a high malaria transmission area. We describe the manifold challenges of enrolling and immunizing 345 soldier participants at their home base in western Indonesia before their nearly 6,000-km voyage to eastern Indonesia, where they are being monitored for incident P. falciparum and Plasmodium vivax malaria cases during 9 months of exposure. The unique regulatory, ethical, and operational complexities of this trial demonstrate the importance of thorough planning, frequent communication, and close follow-up with stakeholders. Effective engagement with the military community and the ability to adapt to unanticipated events have proven key to the success of this trial. © 2024 The author(s)		Adult; Female; Humans; Indonesia; Malaria Vaccines; Malaria, Falciparum; Malaria, Vivax; Male; Military Personnel; Plasmodium falciparum; Plasmodium vivax; Sporozoites; Vaccines, Attenuated; Young Adult; chloroquine; live vaccine; malaria vaccine; placebo; sporozoite vaccine; live vaccine; malaria vaccine; adult; Article; clinical monitoring; clinical outcome; controlled study; disease transmission; double blind procedure; drug efficacy; drug exposure; drug safety; drug tolerability; eligibility; follow up; health care planning; human; immunization; incidence; Indonesian; informed consent; interpersonal communication; major clinical study; malaria falciparum; male; middle aged; military deployment; military personnel; phase 2 clinical trial; Plasmodium vivax malaria; randomization; randomi	Congressionally Directed Medical Research Programs, CDMRP	Financial support: This research is funded by an award from the Congressionally Directed Medical Research Program (CDMRP) to Sanaria Inc. and clinical trial agreement with University of Oxford. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the CDMRP.	American Society of Tropical Medicine and Hygiene	00029637		38531102	Article	Q1	1042	3942	View
410	Adella F.J.; Ammah H.; Siregar G.O.; Harianja M.; Sundari E.S.; Sagara R.; Tarino N.; Hamers R.L.; Bøgh C.; Soebono H.; Grijsen M.L.	Adella, Fidelis J. (57201662508); Ammah, Hapu (58876488900); Siregar, Gladys O. (58876649500); Harianja, Maria (58876435800); Sundari, Evivana S. (58876435900); Sagara, Rahmat (57372907300); Tarino, Nicolas (57213687515); Hamers, Raph L. (23034345900); Bøgh, Claus (6602120205); Soebono, Hardyanto (6508242918); Grijsen, Marlous L. (25225113700)	57201662508; 58876488900; 58876649500; 58876435800; 58876435900; 57372907300; 57213687515; 23034345900; 6602120205; 6508242918; 25225113700	Teledermatology to Improve Access to and Quality of Skin Care in Eastern Indonesia	2024	American Journal of Tropical Medicine and Hygiene	110	2		364	369	5	1	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184661555&doi=10.4269%2fajtmh.23-0218&partnerID=40&md5=4d37423c831c5e378e4c984ec2ed4e36	Sumba Foundation, Sumba, Indonesia; Department of Dermatology and Venereology, Siloam Hospital, Kupang, Indonesia; Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom; Department of Dermatology and Venereology, Gadjah Mada University, Yogyakarta, Indonesia	Adella F.J., Sumba Foundation, Sumba, Indonesia; Ammah H., Sumba Foundation, Sumba, Indonesia; Siregar G.O., Sumba Foundation, Sumba, Indonesia; Harianja M., Sumba Foundation, Sumba, Indonesia; Sundari E.S., Department of Dermatology and Venereology, Siloam Hospital, Kupang, Indonesia; Sagara R., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Tarino N., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Hamers R.L., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom; Bøgh C., Sumba Foundation, Sumba, Indonesia; Soebono H., Department of Dermatology and Venereology, Gadjah Mada University, Yogyakarta, Indonesia; Grijsen M.L., Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom	Skin diseases are a major public health concern in Indonesia, although access to specialized care in remote areas is limited. We initiated a low-cost teledermatology service in Sumba, a remote island in eastern Indonesia. Eighteen healthcare workers (HCWs) at five primary healthcare centers received training to manage common skin diseases and submit clinical cases beyond their expertise to an online platform. Submitted cases were reviewed by at least one dermatologist. Diagnostic agreement between HCWs and dermatologists was calculated. The HCWs participated in a satisfaction survey 2 years after project initiation. Since October 2020, of 10,384 patients presenting with skin complaints in a 24-month period, 307 (3%) were submitted for a teledermatology consultation. The most frequent skin diseases were infections and infestations (n 5 162, 52.8%) and eczematous (85, 27.7%) and inflammatory (17, 5.5%) conditions. Fifty-three patients (17.3%) were diagnosed with a neglected tropical skin disease, including leprosy and scabies. Dermatologist advice was provided within a median of 50 minutes (interquartile range, 18–255 minutes), with 91.9% of consultations occurring within 24 hours. The diagnostic agreement level between HCWs and dermatologists significantly improved over time, from 46.9% in the first 6-month period (k 5 0.45; 95% CI, 0.37–0.54) to 77.2% in the last 6-month period (k 5 0.76; 95% CI, 0.67–0.86; global P, 0.001). The HCWs reported that the teledermatology service was extremely/very useful in supporting daily practice (100%) and improved their knowledge of skin diseases tremendously/a lot (92%). Teledermatology can improve accessibility and quality of skin services in medically underserved areas, providing opportunities for scalability and knowledge transfer to frontline HCWs. Copyright © 2024 The author(s)		Dermatology; Humans; Indonesia; Skin Care; Skin Diseases; Telemedicine; adolescent; adult; Article; child; clinical practice; consultation; controlled study; dermatitis; dermatologist; eczema; female; health care access; health care quality; health service; health survey; human; Indonesia; infestation; leprosy; major clinical study; male; satisfaction; scabies; skin care; skin disease; skin infection; teledermatology; tropical disease; dermatology; epidemiology; Indonesia; skin care; skin disease; telemedicine	DermLink; International League of Dermatological Societies	Funding text 1: Financial support: This project was financially supported by an International League of Dermatological Societies (ILDS) DermLink Grant.; Funding text 2: Design. The teledermatology service, launched on October 8, 2020, is an ongoing collaboration between Universitas Gadjah Mada in Yogyakarta; the Sumba Foundation, a privately funded, nonprofit, nongovernment healthcare provider in	American Society of Tropical Medicine and Hygiene	00029637		38169455	Article	Q1	1042	3942	View
479	Supali T.; Djuardi Y.; Santoso; Sianipar L.R.; Suryaningtyas N.H.; Alfian R.; Destani Y.; Iskandar E.; Astuty H.; Sugianto N.; Fischer P.U.	Supali, Taniawati (6602742029); Djuardi, Yenny (6507800820); Santoso (57221334416); Sianipar, Lita Renata (57212562534); Suryaningtyas, Nungki Hapsari (57221330832); Alfian, Rahmat (57222748640); Destani, Yossi (57222743128); Iskandar, Elisa (57202299885); Astuty, Hendri (57193240808); Sugianto, Noviani (57216629981); Fischer, Peter U. (23567680200)	6602742029; 6507800820; 57221334416; 57212562534; 57221330832; 57222748640; 57222743128; 57202299885; 57193240808; 57216629981; 23567680200	Surveillance and Selective Treatment of Brugia malayi Filariasis Eleven Years after Stopping Mass Drug Administration in Belitung District, Indonesia	2024	American Journal of Tropical Medicine and Hygiene	110	1		111	116	5	0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184909131&doi=10.4269%2fajtmh.23-0255&partnerID=40&md5=6f323c095a054f72ca3c7d9cbff6c584	Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Baturaja Unit for Health Research and Development, National Institute of Health Research and Development, Ministry of Health of Indonesia, South Sumatra, Indonesia; Directorate of Communicable Disease, Prevention, and Control, Indonesia Ministry of Health, Jakarta, Indonesia; Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States; Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Salemba 6, Jakarta, 10430, Indonesia	Supali T., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Salemba 6, Jakarta, 10430, Indonesia; Djuardi Y., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Santoso, Baturaja Unit for Health Research and Development, National Institute of Health Research and Development, Ministry of Health of Indonesia, South Sumatra, Indonesia; Sianipar L.R., Directorate of Communicable Disease, Prevention, and Control, Indonesia Ministry of Health, Jakarta, Indonesia; Suryaningtyas N.H., Baturaja Unit for Health Research and Development, National Institute of Health Research and Development, Ministry of Health of Indonesia, South Sumatra, Indonesia; Alfian R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Destani Y., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Iskandar E., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Astuty H., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sugianto N., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Fischer P.U., Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States	Brugia malayi is the major cause of lymphatic filariasis (LF) in Indonesia. Zoophilic B. malayi was endemic in Belitung district, and mass drug administration (MDA) with diethylcarbamazine (DEC) and albendazole ceased after five annual rounds in 2010. The district passed three transmission assessment surveys (TAS) between 2011 and 2016. As part of the post-TAS3 surveillance of the national LF elimination program, we collected night blood samples for microfilaria (Mf) detection from 1,911 subjects more than 5 years of age in seven villages. A B. malayi Mf prevalence ranging from 1.7% to 5.9% was detected in five villages. Only 2 (5%) of the total 40 Mf-positive subjects were adolescents aged 18 and 19 years old, and 38 (95%) Mf-positive subjects were 21 years and older. Microfilarial densities in infected individuals were mostly low, with 60% of the subjects having Mf densities between 16 and 160 Mf/mL. Triple-drug treatment with ivermectin, DEC, and albendazole (IDA) was given to 36 eligible Mf-positive subjects. Adverse events were mostly mild, and treatment was well tolerated. One year later, 35 of the treated Mf-positive subjects were reexamined, and 33 (94%) had cleared all Mf, while the anti-Bm14 antibody prevalence remained almost unchanged. Results indicate that in B. malayi-endemic areas, post-TAS3 surveillance for Mf in the community may be needed to detect a potential parasite reservoir in adults. Selective treatment with IDA is highly effective in clearing B. malayi Mf and should be used to increase the prospects for LF elimination if MDA is reintroduced. Copyright © 2024 The author(s)		albendazole; antigen; Bm14 antigen; diethylcarbamazine; immunoglobulin antibody; immunoglobulin G4 antibody; ivermectin; unclassified drug; adult; age; arthralgia; Article; blood sampling; blood smear; Brugia malayi; Brugian filariasis; child; combination chemotherapy; controlled study; density; disease elimination; disease reservoir; drug safety; drug tolerability; endemic disease; female; fever; follow up; headache; health survey; human; hypertension; Indonesia; major clinical study; male; Microfilaria; microfilarial density; microfilariasis; microscopy; myalgia; nausea; nonhuman; optical density; preschool child; prevalence; school child; sex difference; treatment duration; village; vomiting	Bill and Melinda Gates Foundation, BMGF	Financial support: This study was supported by grant no. INV-031336 from the Bill & Melinda Gates Foundation to Washington University.	American Society of Tropical Medicine and Hygiene	00029637		38011734	Article	Q1	1042	3942	View
00071161(1)
No records
388	Putera I.; Ten Berge J.C.E.M.; Thiadens A.A.H.J.; Dik W.A.; Agrawal R.; Van Hagen P.M.; La Distia Nora R.; Rombach S.M.	Putera, Ikhwanuliman (56485949000); Ten Berge, Josianne C. E. M. (56601233400); Thiadens, Alberta A. H. J. (26667331700); Dik, Willem A. (6603280038); Agrawal, Rupesh (7201475180); Van Hagen, P. Martin (57210765646); La Distia Nora, Rina (56001881000); Rombach, Saskia M. (58860662800)	56485949000; 56601233400; 26667331700; 6603280038; 7201475180; 57210765646; 56001881000; 58860662800	Relapse in ocular tuberculosis: relapse rate, risk factors and clinical management in a non-endemic country	2024	British Journal of Ophthalmology			325207				0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85191365698&doi=10.1136%2fbjo-2024-325207&partnerID=40&md5=cc971479a63a8c6f67b14dac83185fc4	Department of Ophthalmology, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, Netherlands; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands; Department of Internal Medicine Section Allergy and Clinical Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands; National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore; National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital Nhs Foundation Trust, London, United Kingdom; Lee Kong Chian School of Medicine, Nanyang Technological University of Singapore, Singapore, Singapore; Duke Nus Medical School, Singapore, Singapore	Putera I., Department of Ophthalmology, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, Netherlands, Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands, Department of Internal Medicine Section Allergy and Clinical Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands; Ten Berge J.C.E.M., Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, Netherlands; Thiadens A.A.H.J., Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, Netherlands; Dik W.A., Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands; Agrawal R., National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore, National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital Nhs Foundation Trust, London, United Kingdom, Lee Kong Chian School of Medicine, Nanyang Technological University of Singapore, Singapore, Singapore, Duke Nus Medical School, Singapore, Singapore; Van Hagen P.M., Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands, Department of Internal Medicine Section Allergy and Clinical Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands; La Distia Nora R., Department of Ophthalmology, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands; Rombach S.M., Department of Internal Medicine Section Allergy and Clinical Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands	Aims: To assess the risk of uveitis relapse in ocular tuberculosis (OTB) following clinical inactivity, to analyse clinical factors associated with relapses and to describe the management strategies for relapses. Methods: A retrospective study was conducted on a 10-year patient registry of patients with OTB diagnosed at Erasmus MC in Rotterdam, The Netherlands. Time-to-relapse of uveitis was evaluated with Kaplan-Meier curve and risk factors for relapses were analysed. Results: 93 OTB cases were identified, of which 75 patients achieved clinical inactivity following treatment. The median time to achieve uveitis inactivity was 3.97 months. During a median follow-up of 20.7 months (Q1-Q3: 5.2-81.2) after clinical inactivity, uveitis relapse occurred in 25 of these 75 patients (33.3%). Patients who were considered poor treatment responders for their initial uveitis episode had a significantly higher risk of relapse after achieving clinical inactivity than good responders (adjusted HR=3.84, 95% CI: 1.28 to 11.51). 13 of the 25 relapsed patients experienced multiple uveitis relapse episodes, accounting for 78 eye-relapse episodes during the entire observation period. Over half (46 out of 78, 59.0%) of these episodes were anterior uveitis. A significant number of uveitis relapse episodes (31 episodes, 39.7%) were effectively managed with topical corticosteroids. Conclusions: Our results suggest that approximately one-third of patients with OTB will experience relapse after achieving clinical inactivity. The initial disease course and poor response to treatment predict the likelihood of relapse in the long-term follow-up. Topical corticosteroids were particularly effective in relapse presenting as anterior uveitis. © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.	Infection; Inflammation; Prognosis; Risk Factors; Treatment Medical		Lembaga Pengelola Dana Pendidikan, LPDP, (0004535/MED/D/19/lpdp2021)	IP is supported by Indonesia Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan\u2014LPDP, No: 0004535/MED/D/19/lpdp2021). The funding source had no involvement in the collection, analysis, interpretation, writing of the report and the decision to submit the article for publication.	BMJ Publishing Group	00071161		38609164	Article	Q1	1733	1668	View
00086312(1)
No records
267	Laily I.; Wiggers T.G.H.; Van Steijn N.; Bijsterveld N.; Bakermans A.J.; Froeling M.; Van Den Berg-Faay S.; De Haan F.H.; De Bruin-Bon R.H.A.C.M.; Boekholdt S.M.; Planken R.N.; Verhagen E.; Jorstad H.T.	Laily, Inarota (57215279447); Wiggers, Tom G.H. (57224115171); Van Steijn, Niels (59150259800); Bijsterveld, Nick (57207904836); Bakermans, Adrianus J. (54400805800); Froeling, Martijn (36521041200); Van Den Berg-Faay, Sandra (57215608529); De Haan, Ferdinand H. (57202237111); De Bruin-Bon, Rianne H.A.C.M. (26434606200); Boekholdt, S. Matthijs (55666749700); Planken, R. Nils (58018751200); Verhagen, Evert (6602397078); Jorstad, Harald T. (23492369900)	57215279447; 57224115171; 59150259800; 57207904836; 54400805800; 36521041200; 57215608529; 57202237111; 26434606200; 55666749700; 58018751200; 6602397078; 23492369900	Pre-Participation Screenings Frequently Miss Occult Cardiovascular Conditions in Apparently Healthy Male Middle-Aged First-Time Marathon Runners	2024	Cardiology (Switzerland)	149	3		255	263	8	2	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190382103&doi=10.1159%2f000536553&partnerID=40&md5=783a2b9ff98e0c33bf07187ea5a8525d	Department of Cardiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Department of Public and Occupational Health, Amsterdam Collaboration on Health and Safety in Sports, Amsterdam Movement Sciences, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Center for Sport and Exercise Studies, Indonesian Medical Education and Research Institute, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Sports Medicine, Anna Hospital, Geldrop, Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Department of Radiology, University Medical Center Utrecht, Utrecht, Netherlands; Faculty of Health, School of Physiotherapy, Amsterdam University of Applied Sciences, Amsterdam, Netherlands	Laily I., Department of Cardiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, Department of Public and Occupational Health, Amsterdam Collaboration on Health and Safety in Sports, Amsterdam Movement Sciences, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, Center for Sport and Exercise Studies, Indonesian Medical Education and Research Institute, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Wiggers T.G.H., Department of Cardiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, Department of Sports Medicine, Anna Hospital, Geldrop, Netherlands; Van Steijn N., Department of Cardiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Bijsterveld N., Department of Cardiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Bakermans A.J., Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Froeling M., Department of Radiology, University Medical Center Utrecht, Utrecht, Netherlands; Van Den Berg-Faay S., Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; De Haan F.H., Faculty of Health, School of Physiotherapy, Amsterdam University of Applied Sciences, Amsterdam, Netherlands; De Bruin-Bon R.H.A.C.M., Department of Cardiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Boekholdt S.M., Department of Cardiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Planken R.N., Department of Cardiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Verhagen E., Department of Public and Occupational Health, Amsterdam Collaboration on Health and Safety in Sports, Amsterdam Movement Sciences, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Jorstad H.T., Department of Cardiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands	Introduction: The optimal pre-participation screening strategy to identify athletes at risk for exercise-induced cardiovascular events is unknown. We therefore aimed to compare the American College of Sports Medicine (ACSM) and European Society of Cardiology (ESC) pre-participation screening strategies against extensive cardiovascular evaluations in identifying high-risk individuals among 35.50- year-old apparently healthy men. Methods: We applied ACSM and ESC pre-participation screenings to 25 men participating in a study on first-time marathon running. We compared screening outcomes against medical history, physical examination, electrocardiography, blood tests, echocardiography, cardiopulmonary exercise testing, and magnetic resonance imaging. Results: ACSM screening classified all participants as "medical clearance not necessary."ESC screening classified two participants as "high-risk."Extensive cardiovascular evaluations revealed ≥1 minor abnormality and/or cardiovascular condition in 17 participants, including three subjects with mitral regurgitation and one with a small atrial septal defect. Eleven participants had dyslipidaemia, six had hypertension, and two had premature atherosclerosis. Ultimately, three (12%) subjects had a serious cardiovascular condition warranting sports restrictions: aortic aneurysm, hypertrophic cardiomyopathy (HCM), and myocardial fibrosis post-myocarditis. Of these three participants, only one had been identified as "high-risk"by the ESC screening (for dyslipidaemia, not HCM) and none by the ACSM screening. Conclusion: Numerous occult cardiovascular conditions are missed when applying current ACSM/ ESC screening strategies to apparently healthy middle-aged men engaging in their first high-intensity endurance sports event. © 2024 The Author(s). Published by S. Karger AG, Basel.	Adult; Cardiology; Exercise; Marathon running; Myocardial diseases; Sports medicine	Adult; Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Dyslipidemias; Echocardiography; Electrocardiography; Exercise Test; Humans; Hypertension; Magnetic Resonance Imaging; Male; Marathon Running; Mass Screening; Middle Aged; Missed Diagnosis; Physical Examination; apolipoprotein B; beta adrenergic receptor blocking agent; low density lipoprotein cholesterol; triacylglycerol; troponin T; adult; aortic aneurysm; Article; atherosclerotic plaque; cardiology; cardiometabolic risk; cardiomyopathy; cardiovascular magnetic resonance; cardiovascular risk; computer assisted tomography; dyslipidemia; dyspnea; echocardiography; electrocardiography; female; fibrosis; heart muscle fibrosis; human; hypercholesterolemia; hypertension; hypertrophic cardiomyopathy; male; marathon runner; medical hi	Lembaga Pengelola Dana Pendidikan, LPDP, (201803220412678); Lembaga Pengelola Dana Pendidikan, LPDP	This work is supported by the Indonesia Endowment Fund for Education (LPDP \u2013 Grant No. 201803220412678). The funder had no role in the design, data collection, data analysis, and reporting of this study.	S. Karger AG	00086312		38325343	Article	#N/A	#N/A	#N/A	View
00122823(1)
No records
416	Tanaka H.; Oka S.; Shiotani A.; Sugimoto M.; Suzuki H.; Naito Y.; Handa O.; Hisamatsu T.; Fukudo S.; Fujishiro M.; Motoya S.; Yahagi N.; Yamaguchi S.; Chan F.K.L.; Lee S.-Y.; Li B.; Ang T.L.; Abdullah M.; Tablante M.C.; Prachayakul V.; Tanaka S.	Tanaka, Hidenori (57195921838); Oka, Shiro (7201600764); Shiotani, Akiko (55559820600); Sugimoto, Mitsushige (8265532300); Suzuki, Hidekazu (57218118213); Naito, Yuji (55138675100); Handa, Osamu (6602192347); Hisamatsu, Tadakazu (57209454238); Fukudo, Shin (57219719431); Fujishiro, Mitsuhiro (7005568709); Motoya, Satoshi (57195547525); Yahagi, Naohisa (7006607032); Yamaguchi, Satoru (26024567400); Chan, Francis K.L. (55512627500); Lee, Sun-Young (56452230800); Li, Baiwen (55613301900); Ang, Tiin	57195921838; 7201600764; 55559820600; 8265532300; 57218118213; 55138675100; 6602192347; 57209454238; 57219719431; 7005568709; 57195547525; 7006607032; 26024567400; 55512627500; 56452230800; 55613301900; 8604912300; 7103393434; 57196122455; 26024459800; 57211770789	Current Status of Diagnosis and Treatment of Colorectal Cancer in Asian Countries: A Questionnaire Survey	2024	Digestion	105	1		62	68	6	0	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85168686534&doi=10.1159%2f000531706&partnerID=40&md5=e496e97099d2a5a5e8b1993393767ef6	Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan; Department of Gastroenterology, Hiroshima University Hospital, Hiroshima, Japan; Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan; Department of Gastroenterological Endoscopy, Tokyo Medical University Hospital, Tokyo, Japan; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan; Department of Human Immunology and Nutrition Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan; Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan; Division of Research and Development for Minimally Invasive Treatment, Cancer Center, Keio University School of Medicine, Tokyo, Japan; Department of Surgery, Dokkyo Medical University Nikko Medical Center, Nikko, Japan; Department Medicine and Therapeutics, Institute of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong; Department of Internal Medicine, Division of Gastroenterology, Konkuk University School of Medicine, Seoul, South Korea; Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Department of Gastroenterology and Hepatology, Changi General Hospital, Duke-NUS Medical School, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Division of Gastroenterology Pancreatobiliary and Digestive Endoscopy, Department of Internal Medicine, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department Internal Medicine, Section of Gastroenterology and Hepatology, University of Santo Tomas Hospital, Manila, Philippines; Division of Gastroenterology, Department Internal Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand	Tanaka H., Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan; Oka S., Department of Gastroenterology, Hiroshima University Hospital, Hiroshima, Japan; Shiotani A., Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan; Sugimoto M., Department of Gastroenterological Endoscopy, Tokyo Medical University Hospital, Tokyo, Japan; Suzuki H., Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan; Naito Y., Department of Human Immunology and Nutrition Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Handa O., Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan; Hisamatsu T., Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan; Fukudo S., Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; Fujishiro M., Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Motoya S., IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan; Yahagi N., Division of Research and Development for Minimally Invasive Treatment, Cancer Center, Keio University School of Medicine, Tokyo, Japan; Yamaguchi S., Department of Surgery, Dokkyo Medical University Nikko Medical Center, Nikko, Japan; Chan F.K.L., Department Medicine and Therapeutics, Institute of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong; Lee S.-Y., Department of Internal Medicine, Division of Gastroenterology, Konkuk University School of Medicine, Seoul, South Korea; Li B., Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Ang T.L., Department of Gastroenterology and Hepatology, Changi General Hospital, Duke-NUS Medical School, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Abdullah M., Division of Gastroenterology Pancreatobiliary and Digestive Endoscopy, Department of Internal Medicine, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Tablante M.C., Department Internal Medicine, Section of Gastroenterology and Hepatology, University of Santo Tomas Hospital, Manila, Philippines; Prachayakul V., Division of Gastroenterology, Department Internal Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Tanaka S., Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan	Introduction: Diagnostic and therapeutic methods for colorectal cancer (CRC) have advanced; however, they may be inaccessible worldwide, and their widespread use is challenging. This questionnaire survey investigates the current status of diagnosis and treatment of early-stage CRC in Asian countries. Methods: Responses to the questionnaire were obtained from 213 doctors at different institutions in 8 countries and regions. The questionnaire consisted of 39 questions on the following four topics: noninvasive diagnosis other than endoscopy (6 questions), diagnosis by magnification and image-enhanced endoscopy (IEE) including artificial intelligence (AI) (10 questions), endoscopic submucosal dissection (ESD), proper use among other therapeutic methods (11 questions), and pathologic diagnosis and surveillance (12 questions). Results: Although 101 of 213 respondents were affiliated with academic hospitals, there were disparities among countries and regions in the dissemination of advanced technologies, such as IEE, AI, and ESD. The NICE classification is widely used for the diagnosis of colorectal tumors using IEE, while the JNET classification with magnification was used in countries such as Japan (65/70, 92.9%) and China (16/22, 72.7%). Of the 211 respondents, 208 (98.6%) assumed that en bloc resection should be achieved for carcinomas, and 180 of 212 (84.9%) believed that ESD was the most suitable in cases with a diameter larger than 2 cm. However, colorectal ESD is not widespread in countries such as Thailand, the Philippines, and Indonesia. Conclusion: The promotion of advanced technologies and education should be continual to enable more people to benefit from them. © 2023 2023 S. Karger AG, Basel.	Colonoscopy; Colorectal cancer; Colorectal tumor; En bloc resection	Artificial Intelligence; Colonoscopy; Colorectal Neoplasms; Dissection; Endoscopic Mucosal Resection; Endoscopy, Gastrointestinal; Humans; Intestinal Mucosa; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; DNA; adult; Article; artificial intelligence; Asian; cancer diagnosis; cancer staging; cancer therapy; China; clinical classification; cold snare polypectomy; colon capsule endoscopy; colonoscopy; colorectal cancer; colorectal tumor; computed tomographic colonography; disease surveillance; en bloc resection; endoscopic mucosal resection; endoscopic submucosal dissection; endoscopic ultrasonography; endoscopy; health survey; histopathology; human; image enhanced endoscopy; image enhancement; Indonesia; information dissemination; lymph vessel metastasis; magnification			S. Karger AG	00122823		37497916	Article	Q2	914	4869	View

Publikasi Scopus 2024 per tanggal 30 Juni 2024 (499 artikel)